<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67094">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01848639</url>
  </required_header>
  <id_info>
    <org_study_id>ALCHEMIST</org_study_id>
    <secondary_id>RB 12-079</secondary_id>
    <nct_id>NCT01848639</nct_id>
  </id_info>
  <brief_title>ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial</brief_title>
  <acronym>ALCHEMIST</acronym>
  <official_title>ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST), Phase III b</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine the effects of spironolactone in comparison to placebo
      on the composite endpoint of nonfatal Myocardial Infarction (MI), hospitalization for heart
      failure, nonfatal stroke or cardiovascular-induced death. The primary endpoint will be the
      time to onset of the first incident.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  During a run-in period : Spironolactone will be initially administered per os at a 25
           mg dose per two days in practice after the session, three times per week

        -  Patients will be randomized (spironolactone vs. placebo) and titrated over one month to
           a maximum single dose of 25 mg/d

        -  However if kalemia is greater than or equal to  5.5 mmol / l twice on this run-in
           period or on the day of randomization, patient won't be randomized.

        -  A pre-specified algorithm for the management of the risk of incident hyperkalemia will
           be followed, including dose adjustment, temporary cessation of study treatment, in
           addition to usual dietary measures and the use of chelating resins and low-potassium
           dialysis baths

        -  Patients will be followed for a mean of 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The time to onset of the first incident :non-fatal MI or hospitalization for heart failure or nonfatal stroke or cardiovascular (CV) death</measure>
    <time_frame>25 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The cumulate rate of nonfatal MI, hospitalization for heart failure, nonfatal stroke or CV death</measure>
    <time_frame>25 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to onset of death from i) any cause and  ii) from a CV event and iii) from a non CV cause</measure>
    <time_frame>25 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time of survival without a major CV event (nonfatal MI, hospitalization for heart failure, non-fatal stroke, cardiac arrest resuscitation)</measure>
    <time_frame>25 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of procedures related to stenosis or vascular access thrombosis for hemodialysis (HD)</measure>
    <time_frame>25 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of coronary or peripheral revascularizations (including lower limb amputations)</measure>
    <time_frame>25 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure and its inter visit variability</measure>
    <time_frame>25 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The occurrence of atrial fibrillation</measure>
    <time_frame>25 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hyperkalemia&gt; 6 mmol/l</measure>
    <time_frame>25 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of the effect of treatment on quality of life.</measure>
    <time_frame>25 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Ancillary study:establishment of a biological collection (serum bank and DNA biobank) for future biomarker studies</measure>
    <time_frame>25 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Ancillary study:morbimortality data</measure>
    <time_frame>3, 5 and 10 years of follow-up after the double-blind study</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">825</enrollment>
  <condition>End Stage Renal Failure on Dialysis</condition>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in  using an algorithm used in the EPHESUS and EMPHASIS-HF trials.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in  using an algorithm used in the EPHESUS and EMPHASIS-HF trials.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in  using an algorithm used in the EPHESUS and EMPHASIS-HF trials.</description>
    <arm_group_label>Spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in  using an algorithm used in the EPHESUS and EMPHASIS-HF trials.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Health insurance beneficiary

          -  Men and women under 80 years of age, on hemodialysis for at least 6 months for
             end-stage renal disease regardless of the aetiology including diabetes, with at least
             3 hemodialysis sessions per week AND presenting at least one of following
             comorbidities or CV risk factors:

          -  left ventricular  mass &gt; 130 g/m2 in men and 100 g/m2 in women measured during the
             twelve months preceding inclusion

          -  left ventricular ejection fraction &lt; 40% measured during the twelve months preceding
             inclusion

          -  diabetes

          -  history of Cardiovascular disease: coronary artery disease, symptomatic lower limb
             peripheral arterial disease, carotid or renal artery stenosis &gt; 50%, stroke,
             hospitalization for heart failure.

        Exclusion Criteria:

          -  history of hypersensitivity to spironolactone or galactose intolerance

          -  the Lapp lactase deficiency or malabsorption of glucose or galactose

          -  hyperkalemia &gt; 5.5 mmol/l during the two weeks prior to enrolment

          -  history of unscheduled hemodialysis for hyperkalemia during the last six months

          -  hospitalization for hyperkalemia during the last six months

          -  patients with imperative indication of a combination of ACEI and sartan or renin
             inhibitor (each being authorized separately), NSAIDS, Cox-2 inhibitors

          -  kidney transplant scheduled within the year

          -  symptomatic interdialytic hypotension

          -  acute systemic disease

          -  uncompensated hypothyroidism

          -  acute hyperthyroidism

          -  co-morbidity with life-threatening prognosis established at 2 years

          -  cardiac transplant

          -  severe uncontrolled arrhythmia

          -  stroke or acute coronary syndrome within 3 months prior to enrolment

          -  recent (3 months) or planned coronary revascularization or cardiovascular surgery
             (excluding HD vascular access)

          -  non menopausal women or without effective contraceptive methods

          -  pregnancy, breastfeeding or planning a pregnancy within 2 years

          -  non compliance

          -  protected adult

          -  SBP &gt; 200 mmHg and/or DBP &gt; 110 mmHg or significant clinico-biological abnormalities
             not directly related to ESRD

          -  Concomitant treatment can not be stopped by another potassium-sparing diuretic, a
             potassium supplements, AINS or Cox 2 inhibitors
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patrick ROSSIGNOL, Pr</last_name>
    <phone>+33383157320</phone>
    <email>p.rossignol@chu-nancy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH Ardeche Nord</name>
      <address>
        <city>Annonay</city>
        <state>Ardeche</state>
        <zip>07100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric LEGRAND, PH</last_name>
    </contact>
    <investigator>
      <last_name>Eric Legrand, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriel CHOUKROUN, PUPH</last_name>
    </contact>
    <investigator>
      <last_name>Gabriel CHOUKROUN, PUPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Verhelst, PH</last_name>
    </contact>
    <investigator>
      <last_name>David Verhelst, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier Ducloux, PH</last_name>
    </contact>
    <investigator>
      <last_name>Didier Ducloux, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Boulogne Sur Mer</name>
      <address>
        <city>Boulogne Sur Mer</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Bataille, PH</last_name>
    </contact>
    <investigator>
      <last_name>Pierre Bataille, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AUB Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique Le Grignou, PH</last_name>
    </contact>
    <investigator>
      <last_name>Dominique Le Grignou, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannick Le Meur, PUPH</last_name>
    </contact>
    <investigator>
      <last_name>Yannick Le Meur, PUPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Henri, PH</last_name>
    </contact>
    <investigator>
      <last_name>Patrick Henri, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Cahors</name>
      <address>
        <city>Cahors</city>
        <zip>46000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lionel Rostaing, PUPH</last_name>
    </contact>
    <investigator>
      <last_name>Lionel Rostaing, PUPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHLM Castelneau</name>
      <address>
        <city>Castelneau Le Lez</city>
        <zip>34170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sébastien Deleuze, PH</last_name>
    </contact>
    <investigator>
      <last_name>Sébastien Deuleuze, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Chambéry</name>
      <address>
        <city>Chambéry</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopitaux Civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mehadji Maaz, PH</last_name>
    </contact>
    <investigator>
      <last_name>Mehadji Maaz, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Haguenau</name>
      <address>
        <city>Haguenau</city>
        <zip>67500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AURAL Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alejandra Lenz, PH</last_name>
    </contact>
    <investigator>
      <last_name>Alejandra Lenz, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Association de Metz</name>
      <address>
        <city>Metz</city>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno Paris, PH</last_name>
    </contact>
    <investigator>
      <last_name>Bruno Paris, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AURAL Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc Frimat, PUPH</last_name>
    </contact>
    <investigator>
      <last_name>Luc Frimat, PUPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Esnault, PUPH</last_name>
    </contact>
    <investigator>
      <last_name>Vincent Esnault, PUPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>AURA Paris 14ème</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Malik Touam, PH</last_name>
    </contact>
    <investigator>
      <last_name>Malik Touam, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Necker</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurélie Hummel, PH</last_name>
    </contact>
    <investigator>
      <last_name>Aurélie Hummel, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP La Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AUB Morlaix</name>
      <address>
        <city>Plourin Lès Morlaix</city>
        <zip>29600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascale Depraetre, PH</last_name>
    </contact>
    <investigator>
      <last_name>Pascale Depraetre, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ARPDD Reims</name>
      <address>
        <city>Reims</city>
        <zip>51726</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AUB Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Laruelle, PH</last_name>
    </contact>
    <investigator>
      <last_name>Eric Laruelle, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécile Vigneau, PUPH</last_name>
    </contact>
    <investigator>
      <last_name>Cécile Vigneau, PUPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ECHO Confluent</name>
      <address>
        <city>Reze</city>
        <zip>44402</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angelo Testa, PH</last_name>
    </contact>
    <investigator>
      <last_name>Angelo Testa, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Perharidy</name>
      <address>
        <city>Roscoff</city>
        <zip>29260</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laëtitia Treguer, PH</last_name>
    </contact>
    <investigator>
      <last_name>Laëtitia Treguer, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franck Le Roy, PH</last_name>
    </contact>
    <investigator>
      <last_name>Franck Le Roy, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHG St Brieuc</name>
      <address>
        <city>St Brieuc</city>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rehouni Boulahrouz, PH</last_name>
    </contact>
    <investigator>
      <last_name>Rehouni Boulahrouz, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nephrocare Tassin-Charcot</name>
      <address>
        <city>St Foy-les-lyon</city>
        <zip>69110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume Jean, PH</last_name>
    </contact>
    <investigator>
      <last_name>Guillaume Jean, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH St Maurice</name>
      <address>
        <city>St Maurice</city>
        <zip>94410</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AURAL Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristian Kunz, PH</last_name>
    </contact>
    <investigator>
      <last_name>Kristian Kunz, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry Hannedouche, PUPH</last_name>
    </contact>
    <investigator>
      <last_name>Thierry Hannedouche, PUPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lionel Rostaing, PUPH</last_name>
    </contact>
    <investigator>
      <last_name>Lionel Rostaing, PUPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maud Francois, PH</last_name>
    </contact>
    <investigator>
      <last_name>Maud Francois, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Valence</name>
      <address>
        <city>Valence</city>
        <zip>26000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Brucker, PH</last_name>
    </contact>
    <investigator>
      <last_name>Marie Brucker, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ALTIR Nancy</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54504</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelly Castin, PH</last_name>
    </contact>
    <investigator>
      <last_name>Nelly Castin, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Privés de Metz- Hôpital Robert Schuman</name>
      <address>
        <city>Vantoux</city>
        <zip>57070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Verdun</name>
      <address>
        <city>Verdun</city>
        <zip>55107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Bindi, PH</last_name>
    </contact>
    <investigator>
      <last_name>Pascal Bindi, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital du Lamentin Martinique</name>
      <address>
        <city>Le Lamentin</city>
        <zip>97232</zip>
        <country>Martinique</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Marc Dueymes, PH</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Marc Dueymes, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Martinique</country>
  </location_countries>
  <removed_countries>
    <country>Guadeloupe</country>
  </removed_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 18, 2013</lastchanged_date>
  <firstreceived_date>May 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic kidney disease</keyword>
  <keyword>end-stage renal disease</keyword>
  <keyword>hemodialysis (ESRD)</keyword>
  <keyword>cardiovascular morbimortality</keyword>
  <keyword>aldosterone antagonist</keyword>
  <keyword>spironolactone</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aldosterone Antagonists</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
